CCL5 and breast carcinoma: Overall, specialized TI-NK cell subsets contribute to the efficacy of anti-HER2 antibodies in primary breast cancer patients by triggering an early and coordinated production of CCL5/IFN-ɣ-CXCL9/10 chemokine axis which facilitates the subsequent recruitment /differentiation of adaptive anti-tumor immunity.